📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. (2022)

First Author: Chanchlani N

Attributed to: King's Health Partners Confidence in Concept funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/ecco-jcc/jjab153

PubMed Identifier: 34473254

Publication URI: http://europepmc.org/abstract/MED/34473254

Type: Journal Article/Review

Volume: 16

Parent Publication: Journal of Crohn's & colitis

Issue: 3

ISSN: 1873-9946